A detailed history of D. E. Shaw & Co., Inc. transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 355,949 shares of HRMY stock, worth $12.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
355,949
Holding current value
$12.1 Million
% of portfolio
0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$30.0 - $39.95 $1.38 Million - $1.84 Million
45,945 Added 14.82%
355,949 $14.2 Million
Q2 2024

Aug 14, 2024

BUY
$28.81 - $33.01 $880,692 - $1.01 Million
30,569 Added 10.94%
310,004 $9.35 Million
Q1 2024

May 15, 2024

SELL
$29.93 - $35.06 $69,467 - $81,374
-2,321 Reduced 0.82%
279,435 $9.38 Million
Q4 2023

Feb 14, 2024

BUY
$19.2 - $33.78 $267,705 - $470,994
13,943 Added 5.21%
281,756 $9.1 Million
Q3 2023

Nov 14, 2023

BUY
$31.89 - $39.03 $872,255 - $1.07 Million
27,352 Added 11.37%
267,813 $8.78 Million
Q2 2023

Aug 14, 2023

BUY
$30.5 - $37.4 $1.4 Million - $1.72 Million
45,975 Added 23.64%
240,461 $8.46 Million
Q1 2023

May 15, 2023

SELL
$30.8 - $53.92 $908,138 - $1.59 Million
-29,485 Reduced 13.16%
194,486 $6.35 Million
Q4 2022

Feb 14, 2023

BUY
$45.4 - $60.91 $8.07 Million - $10.8 Million
177,772 Added 384.8%
223,971 $12.3 Million
Q3 2022

Nov 14, 2022

BUY
$42.06 - $55.45 $396,331 - $522,505
9,423 Added 25.62%
46,199 $2.05 Million
Q2 2022

Aug 15, 2022

BUY
$33.54 - $52.15 $278,952 - $433,731
8,317 Added 29.22%
36,776 $1.79 Million
Q1 2022

May 16, 2022

BUY
$33.14 - $51.13 $943,131 - $1.46 Million
28,459 New
28,459 $1.39 Million
Q3 2021

Nov 15, 2021

SELL
$25.68 - $38.61 $1.15 Million - $1.73 Million
-44,765 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$25.96 - $33.44 $1.16 Million - $1.5 Million
44,765 New
44,765 $1.26 Million

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.02B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.